Merck & Co, the big US drugmaker, is in talks to acquire the biopharmaceuticals company Cubist Pharmaceuticals Inc for more than US$7 billion, according to people briefed on the matter.
The deal, if announced, would represent another multibillion-US dollar healthcare transaction in a banner year for mergers and acquisitions in the industry.
It would also fit into the strategy by Merck’s chief executive, Kenneth Frazier, of buying successful midsize drugmakers that complement his company’s existing stable of drugs.
Merck is expected to pay roughly US$100 a share for Cubist, valuing the company in the range of US$7.5 billion, these people said.
A deal could be announced as early as next week.
Cubist makes drugs that treat dangerous bacteria and superbugs.
Shares in Cubist are trading near a high, nearly doubling in value over the past two years, making it an ideal time for the company’s board to approve a sale.
Unlike many pharmaceutical companies, Cubist focuses on developing drugs that address “significant unmet medical needs,” like diseases that could cause pandemics in the developing world.
Last month, Cubist, which is based in Lexington, Massachusetts, reported third-quarter sales of US$309 million, a 16 percent increase from the same period a year earlier.
Shares of Cubist closed at US$74.36 a share on Friday, with a market value of less than US$6 billion.
Merck appears to be willing to pay about a 33 percent premium for the company, according to the people briefed on the matter.
It was not immediately clear if Merck would pay for Cubist shares with cash, stock or a mix of the two.
Merck, the second-largest US drugmaker behind Pfizer Inc, makes vaccines, prescription products and oncology treatments, and has a market value of more than US$174 billion.
In the third quarter, Merck, based in New Jersey, reported sales of US$10.56 billion and earnings of nearly US$900 million.
Though that was on the low end of analyst expectations, the company’s stock has performed well over the past month and is also trading at highs.
Its shares closed at US$61.49 on Friday.
Part of the cause for Merck’s sales slump, particularly in its vaccine for cervical cancer, is increased competition from generic drugmakers.
However, sales of Merck’s diabetes drugs — its largest line of pharmaceuticals — continues to grow.
Its cash reserves were further bolstered this year when Merck sold its consumer business to Bayer for US$14.2 billion. That deal closed in October.
In June, Merck agreed to buy Idenix Pharmaceuticals for US$3.85 billion, continuing its strategy of pursuing small bolt-on acquisitions rather than megadeals.
Last month, Merck increased its quarterly dividend by a cent, to US$0.44 a share.
DECOUPLING? In a sign of deeper US-China technology decoupling, Apple has held initial talks about using Baidu’s generative AI technology in its iPhones, the Wall Street Journal said China has introduced guidelines to phase out US microprocessors from Intel Corp and Advanced Micro Devices Inc (AMD) from government PCs and servers, the Financial Times reported yesterday. The procurement guidance also seeks to sideline Microsoft Corp’s Windows operating system and foreign-made database software in favor of domestic options, the report said. Chinese officials have begun following the guidelines, which were unveiled in December last year, the report said. They order government agencies above the township level to include criteria requiring “safe and reliable” processors and operating systems when making purchases, the newspaper said. The US has been aiming to boost domestic semiconductor
Nvidia Corp earned its US$2.2 trillion market cap by producing artificial intelligence (AI) chips that have become the lifeblood powering the new era of generative AI developers from start-ups to Microsoft Corp, OpenAI and Google parent Alphabet Inc. Almost as important to its hardware is the company’s nearly 20 years’ worth of computer code, which helps make competition with the company nearly impossible. More than 4 million global developers rely on Nvidia’s CUDA software platform to build AI and other apps. Now a coalition of tech companies that includes Qualcomm Inc, Google and Intel Corp plans to loosen Nvidia’s chokehold by going
ENERGY IMPACT: The electricity rate hike is expected to add about NT$4 billion to TSMC’s electricity bill a year and cut its annual earnings per share by about NT$0.154 Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) has left its long-term gross margin target unchanged despite the government deciding on Friday to raise electricity rates. One of the heaviest power consuming manufacturers in Taiwan, TSMC said it always respects the government’s energy policy and would continue to operate its fabs by making efforts in energy conservation. The chipmaker said it has left a long-term goal of more than 53 percent in gross margin unchanged. The Ministry of Economic Affairs concluded a power rate evaluation meeting on Friday, announcing electricity tariffs would go up by 11 percent on average to about NT$3.4518 per kilowatt-hour (kWh)
OPENING ADDRESS: The CEO is to give a speech on the future of high-performance computing and artificial intelligence at the trade show’s opening on June 3, TAITRA said Advanced Micro Devices Inc (AMD) chairperson and chief executive officer Lisa Su (蘇姿丰) is to deliver the opening keynote speech at Computex Taipei this year, the event’s organizer said in a statement yesterday. Su is to give a speech on the future of high-performance computing (HPC) in the artificial intelligence (AI) era to open Computex, one of the world’s largest computer and technology trade events, at 9:30am on June 3, the Taiwan External Trade Development Council (TAITRA) said. Su is to explore how AMD and the company’s strategic technology partners are pushing the limits of AI and HPC, from data centers to